Asian stocks rise after Moderna's coronavirus vaccine delivers early positive results
The biotech firm reported on Monday that the vaccine produced protective antibodies in all eight of its volunteers, potentially marking a breakthrough moment in the fight against the coronavirus pandemic."All companies searching for a vaccine like to say they are doing well: it's very much in their interest. This was a sample of less than 10 when phase two, starting in months, will be on many thousands," analysts at Rabobank said in a note.
"Even if that hurdle is passed with flying colors we will still not see a vaccine on the US market, let alone in emerging markets, until early 2021."Asian indexes climbed with China's Shanghai Composite up 0.8%, Hong Kong's
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Far East Movement Debuts New Song for Asian Pacific American Heritage Month (EXCLUSIVE)Jay Park, Miyavi, Raja Kumari, MILCK, Lyrics Born and Yuna are just a few of the performers scheduled for “Identity: Project Blue Marble,” an eight-hour relief event in honor of Asian P…
Lire la suite »
Ceramic artist creates hyper-realistic replicas of Asian foodsBrooklyn-based ceramic artist Stephanie Shih has been sculpting foods that resonate with the Asian American community.
Lire la suite »
Moderna's stock soars on positive early-stage data for its coronavirus vaccine candidateShares of Moderna Inc. jumped 25.1% in premarket trading on Monday after the biotechnology company announced positive results from a Phase 1 clinical trial for its experimental mRNA coronavirus vaccine. The trial was done in partnership with the National Institute of Allergy and Infectious Diseases. Within 43 days and after two doses, the participants taking one of two dosing levels of the vaccine candidate reported the same or higher level of antibodies as in blood samples gathered by patients who have recovered from COVID-19, the company said. There were four adverse events during the trial, including one participant who reported a severe skin reaction where the investigational vaccine was administered. "These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25" micrograms, Moderna chief medical officer Dr. Tal Zaks said in a news release. The next step is a Phase 2 trial, which has been approved to move forward by the Food and Drug Administration. It will focus on two dosing levels (50 microgram and 100 microgram). The early-stage trial had a third dosing level, 250 micrograms. Moderna's vaccine candidate is widely viewed as a frontrunner in the effort to develop the first vaccine for the virus. The preclinical company said earlier this month that the Phase 2 trial will begin "shortly," and on Monday it said it expects a Phase 3 trial to begin in July, if the vaccine is successful in the mid-stage trial. Moderna's stock has soared 240.9% year-to-date. The S&P 500 , in comparison, is down 11.3%.
Lire la suite »
Stocks rebound as positive Moderna vaccine trial boosts optimism for economic recoveryStocks bounced back Monday on optimism the U.S. economy may start to recover from the coronavirus pandemic after drugmaker Moderna released promising early results for a vaccine.
Lire la suite »